Etelcalcetide (Parsabiv): Uses, Evidence, and Side Effects

Patients on hemodialysis with secondary hyperparathyroidism often need a way to bring parathyroid hormone under control without adding pill burden. Etelcalcetide, sold as Parsabiv, is an FDA-approved injectable option built for this exact setting.

Key takeaways

• Etelcalcetide (Parsabiv) is approved for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
• It works as a calcimimetic, activating the calcium-sensing receptor to lower PTH secretion.
• It is not recommended for parathyroid carcinoma, primary hyperparathyroidism, or CKD patients not on hemodialysis.
• Across 24 registered trials, studies span pediatric, pharmacokinetic, and safety evaluations in hemodialysis patients.
• FAERS reports for etelcalcetide most frequently mention underdosing, shunt problems, nausea, and low blood calcium.

What Etelcalcetide Is

Etelcalcetide is a calcimimetic agent, meaning it mimics the effect of calcium on a specific cell receptor. It binds to the calcium-sensing receptor (CaSR) and boosts the receptor's response to calcium already in the blood. When this receptor on parathyroid chief cells is activated, the cells release less parathyroid hormone (PTH). This mechanism is the basis for its use in conditions where PTH is chronically elevated.

What Etelcalcetide Is Approved For

Etelcalcetide, marketed as Parsabiv, is approved to treat secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis. The label specifically limits its use: it has not been studied in patients with parathyroid carcinoma, primary hyperparathyroidism, or chronic kidney disease without hemodialysis, and is not recommended for those groups. No boxed warning is listed on the label.

What the Evidence Shows

Etelcalcetide has been studied across 24 registered clinical trials. Early pharmacokinetic and safety work includes a completed Phase 1 study evaluating safety, tolerability, and pharmacokinetics in hemodialysis patients with secondary hyperparathyroidism. A separate completed Phase 1 study looked at a single dose in pediatric patients aged 2 to under 18 years undergoing hemodialysis, reflecting continued interest in the drug's use across age groups within its approved dialysis population.

Reported Side Effects

Reports submitted to FAERS for etelcalcetide are counts of adverse event reports, not confirmed rates of incidence or proof that the drug caused the event. The most frequently reported issues involve dosing and device related events, including underdose (247 reports) and product storage error (149), alongside vascular access complications such as shunt stenosis (204) and shunt occlusion (127). Calcium and parathyroid related changes are also commonly reported, including hypocalcaemia (149), decreased blood calcium (124), and increased blood parathyroid hormone (145). Nausea (192) was the most reported general symptom.